While data on liver or cardiac events (e.g., liver fibrosis/cirrhosis, portal hypertension, ischemic heart disease) are documented as part of real‐world patient follow‐up, these outcomes are infrequent, thus limiting extrapolation of ALT or AST data to clinical outcomes. This evidence concerns the gene GPT and portal hypertension.